Molecular Targeting Technologies, Inc.

Quick facts

Phase 1 pipeline

• 177Lu-DOTA-EB-TATE · Oncology
  Somatostatin receptor targeting

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Molecular Targeting Technologies, Inc. portfolio CI brief
• Molecular Targeting Technologies, Inc. pipeline updates RSS